{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:28:24Z","timestamp":1786512504964,"version":"build-2736575974"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014337","name":"Menarini Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"\n Background<\/jats:title>\n Tagraxofusp is a first-in-class CD123-targeted therapy approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN). Although venetoclax is not approved for BPDCN, limited use has been reported. We evaluated overall survival (OS) and healthcare resource utilization in patients with BPDCN treated with tagraxofusp- or venetoclax-based regimens in a US real-world setting.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Claims data were analyzed from patients with \u22651 BPDCN diagnosis (January 2016-December 2023) and initiation of tagraxofusp- or venetoclax-based therapy. Index date was defined as first inpatient tagraxofusp dosing or venetoclax-based therapy initiation. Patients were matched 1:1 by line of therapy (LOT).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Each cohort had 47 patients. Tagraxofusp-based treatment was associated with longer median OS versus venetoclax-based (35.3 vs 10.5 months), consistent across patients receiving monotherapy, combination, or transplantation. Tagraxofusp-treated patients were more likely to proceed to subsequent LOT versus venetoclax-treated (47% vs 11%). During months 2-6, tagraxofusp reduced median inpatient hospitalization duration (3 vs 7 days) and transfusion rates (3% vs 32%) versus venetoclax.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n In this retrospective claims-based analysis, tagraxofusp was associated with longer survival versus venetoclax, including across treatment contexts. These real-world results are consistent with the established role of tagraxofusp as the first-line standard of care for patients with BPDCN, irrespective of transplant eligibility, and support continued evaluation of tagraxofusp-based regimens as a backbone for future combinations.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fonc.2026.1903818","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:44:59Z","timestamp":1786509899000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Longer survival and favorable healthcare resource utilization of tagraxofusp versus venetoclax in patients with blastic plasmacytoid dendritic cell neoplasm: results of a real-world analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Anthony S.","family":"Stein","sequence":"first","affiliation":[{"name":"City of Hope","place":["Duarte, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guru Subramanian","family":"Guru Murthy","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin","place":["Milwaukee, WI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankit","family":"Vachhani","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham","place":["Birmingham, AL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Iyer","sequence":"additional","affiliation":[{"name":"Columbia University","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yipeng","family":"Gao","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Katsetos","sequence":"additional","affiliation":[{"name":"Menarini Group","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Pelletier","sequence":"additional","affiliation":[{"name":"Menarini Group","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibor","family":"Kovacsovics","sequence":"additional","affiliation":[{"name":"City of Hope","place":["Goodyear, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.12.010","article-title":"Recent advances in the biology and Cd123-directed treatment of blastic plasmacytoid dendritic cell neoplasm","volume":"24","author":"Pemmaraju","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0025","article-title":"Acute myeloid leukemia, version 3.2023, Nccn clinical practice guidelines in oncology","volume":"21","author":"Pollyea","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719874733","article-title":"Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm","volume":"10","author":"Economides","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.7026","article-title":"Blastic plasmacytoid dendritic cell neoplasm","volume":"21","author":"Jain","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017865","article-title":"North American blastic plasmacytoid dendritic cell neoplasm consortium: Position on standards of care and areas of need","volume":"141","author":"Pemmaraju","year":"2023","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.6004\/jadpro.2025.16.7.21","article-title":"Care optimization for patients with blastic plasmacytoid dendritic cell neoplasm receiving tagraxofusp","author":"Faysman","year":"2025","journal-title":"J Adv Pract Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024262","article-title":"How I treat blastic plasmacytoid dendritic cell neoplasm","volume":"145","author":"Kharfan-Dabaja","year":"2025","journal-title":"Blood"},{"key":"B8","unstructured":"2023"},{"key":"B9","unstructured":"Cha\n \n 2021"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00034","article-title":"Long-term benefits of tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm","volume":"40","author":"Pemmaraju","year":"2022","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2595226","article-title":"Durable post-transplant survival after first-line tagraxofusp for blastic plasmacytoid dendritic cell neoplasm","volume":"67","author":"Pemmaraju","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70209","article-title":"First-line tagraxofusp induces durable responses with prolonged survival in adults younger than 50\u2009years with blastic plasmacytoid dendritic cell neoplasm: Post hoc analysis of a phase 2 trial","volume":"207","author":"Stein","year":"2025","journal-title":"Br J Haematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.300036","article-title":"First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness level","volume":"111","author":"Pemmaraju","year":"2026","journal-title":"Haematologica"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06493-w","article-title":"Durable outcomes with manageable safety leading to prolonged survival with tagraxofusp for treatment-na\u00efve patients with blastic plasmacytoid dendritic cell neoplasm: Real world results from a European named patient program","volume":"104","author":"Herling","year":"2025","journal-title":"Ann Hematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70243","article-title":"Hematopoietic effects of tagraxofusp in treatment-na\u00efve patients with blastic plasmacytoid dendritic cell neoplasm","volume":"132","author":"Konopleva","year":"2026","journal-title":"Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2553862","article-title":"Real-world study of tagraxofusp monotherapy in relapsed or refractory blastic plasmacytoid dendritic cell neoplasm","volume":"66","author":"Angelucci","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-653","article-title":"Tagraxofusp, azacitidine, and venetoclax (Tag-Aza-Ven) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendritic cell neoplasm (Bpdcn): Results of a phase 2 trial","volume":"146","author":"Lane","year":"2025","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41408-025-01346-1","article-title":"Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms","volume":"15","author":"Gangat","year":"2025","journal-title":"Blood Cancer J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-16-0999","article-title":"Blastic plasmacytoid dendritic cell neoplasm is dependent on Bcl2 and sensitive to venetoclax","volume":"7","author":"Montero","year":"2017","journal-title":"Cancer Discov"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1808354","article-title":"Venetoclax in a patient with a blastic plasmacytoid dendritic-cell neoplasm","volume":"379","author":"Agha","year":"2018","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2019.106199","article-title":"Venetoclax to treat relapsed blastic plasmacytoid dendritic cell neoplasm: A case-report and review of literature","volume":"85","author":"Beziat","year":"2019","journal-title":"Leuk Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s13256-021-02939-7","article-title":"Venetoclax in relapsed\/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: A case report and review of the literature","volume":"15","author":"Albiol","year":"2021","journal-title":"J Med Case Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04718-2","article-title":"Achievement of rapid complete remission in an 87-year-old female patient with azacytidine-venetoclax for blastic plasmacytoid dendritic cell neoplasm","volume":"101","author":"Le Calloch","year":"2022","journal-title":"Ann Hematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.0318-22","article-title":"Venetoclax combined with azacytidine can be a first-line treatment option for elderly blastic plasmacytoid dendritic cell neoplasm","volume":"62","author":"Nagate","year":"2023","journal-title":"Intern Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.52446","article-title":"Blastic plasmacytoid dendritic cell neoplasm in long-term complete remission after venetoclax monotherapy","volume":"16","author":"Sasaki","year":"2024","journal-title":"Cureus"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1425833","article-title":"Venetoclax combined with azacitidine in blastic plasmacytoid dendritic cell neoplasm: A case report and comprehensive review on the current and future treatment","volume":"11","author":"Wang","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26417","article-title":"Venetoclax and hypomethylating agents in older\/unfit patients with blastic plasmacytoid dendritic cell neoplasm","volume":"97","author":"Gangat","year":"2022","journal-title":"Am J Hematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the Bcl2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid Malignancies","volume":"93","author":"DiNardo","year":"2018","journal-title":"Am J Hematol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06221-4","article-title":"Venetoclax and hypomethylating agents versus tagraxofusp in older patients with blastic plasmacytoid dendritic cell neoplasm","volume":"104","author":"Lee","year":"2025","journal-title":"Ann Hematol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2025.100086","article-title":"Prospective clinical trials of venetoclax and hypomethylating agents for relapsed Bpdcn","volume":"2","author":"Pemmaraju","year":"2025","journal-title":"Blood Neoplasia"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in Icd-9-Cm and Icd-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"B33","article-title":"Charlson comorbidity index: Icd-9 update and Icd-10 translation","volume":"12","author":"Glasheen","year":"2019","journal-title":"Am Health Drug Benefits"},{"key":"B34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2307\/2530286","article-title":"A confidence interval for the median survival time","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1903818\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:45:13Z","timestamp":1786509913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1903818\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":34,"alternative-id":["10.3389\/fonc.2026.1903818"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1903818","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"1903818"}}